Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Abstract Background No study has performed a face-to-face comparison of biologics after the failure of the first anti-TNF agent in patients with Crohn’s disease (CD). The aim of the study was to compare the efficacy of biologics in this setting. Methods Patients with CD who were refractory to a firs...

Full description

Bibliographic Details
Main Authors: Rayer Cassandra, Maria Nachury, Bourreille Arnaud, Roblin Xavier, Peyrin-Biroulet Laurent, Viennot Stephanie, Flamant Mathurin, Laharie David, Caron Bénédicte, Dewitte Marie, Siproudhis Laurent, Fumery Mathurin, Bouguen Guillaume
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Gastroenterology
Subjects:
Crohn’s disease
Anti-TNF
Vedolizumab
Ustekinumab
Treatment strategy
Second line
Online Access:https://doi.org/10.1186/s12876-022-02583-5

Internet

https://doi.org/10.1186/s12876-022-02583-5

Similar Items